Vivian Li | Early Stage Investor
K2VC

Dr. Vivian Li holds a PhD in Biomedical Sciences from The Chinese University of Hong Kong and an MBA from Johns Hopkins University, with a distinguished background bridging science and business on a global scale. She conducted postdoctoral research at the University of Pennsylvania and worked in drug development at GlaxoSmithKline, gaining expertise in drug discovery, IND-enabling studies, and biomarker development. Transitioning into early-stage biotech investment and business development, Dr. Li now leverages her scientific expertise, strategic vision, and deal-making skills to accelerate the commercialization of groundbreaking innovations.   She is actively evaluating early-stage biotech and platform-driven drug discovery opportunities. With incubation experience, she supports team building, vendor selection, fundraising, and licensing. She also works with portfolio companies that are exploring investment, business development, or newco collaboration opportunities.   K2 Venture Partners is a venture capital fund founded in 2016 that focuses on investments in biotech, medtech, and life science companies at the early stage. The firm supports exceptional scientists and entrepreneurs worldwide in translating innovative technology platforms into valuable, high-impact therapeutics and applications. K2 strives to be a leading institutional investor by providing hands-on support and acting as a long-term partner. Its typical check size ranges from $5M to $15M, with an investment focus on early-stage opportunities-primarily angel through Series A. The firm is therapeutic-area and modality agnostic and is open to incubation opportunities when appropriate.   Website: https://www.k2vc.com/en LinkedIn: http://www.linkedin.com/in/mingyue-vivian-li-962221124 WeChat: 13601951229